ConductScience.org, home

Trial · NCT07885436

68Ga-XHER2 PET/CT for HER2 Assessment

NCT07885436, Not applicable, Recruiting, The First Affiliated Hospital of Xiamen University

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. 68Ga-XHER2 PET/CT for HER2 Assessment. Trials, record NCT07885436. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885436

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
68Ga-XHER2 PET/CT for HER2 Assessment
NCT number
NCT07885436
Status
Recruiting
Phases
Not applicable
Enrollment
80 participants, estimated
Lead sponsor
The First Affiliated Hospital of Xiamen University
Conditions
Solid Tumor (Excluding CNS), HER2, PET / CT
Interventions
68Ga-XHER2 PET/CT
First posted
2026-10-21
Last updated
2026-10-21

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryEvaluate the feasibility of PET/CT imaging with 68Ga-XHER2 for the non-invasive assessment of HER2 expression in various cancer types.1monthTumor HER2 expression analysis in a fresh biopsy sample will be correlated to 68Ga-XHER2 tumor uptake, evaluated by measuring standardized uptake value (SUV) on the 68Ga-XHER2PET/CT.
SecondaryDescription of 68Ga-XHER2 uptake by measuring standardized uptake value (SUV) in various types of tumors1 monthStandardized uptake value (SUV) of 68Ga-XHER2 PET/CT for each target lesion of subject or suspected primary tumor or/and metastasis.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07885436

GET https://conductscience.org/api/trials/v1/NCT07885436/registered